Hemogenyx Pharmaceuticals — First Patient Treated in Second Adult Dose Cohort

Hemogenyx has begun treating the second cohort in its Phase I CAR-T trial at double dose.

What the company is saying

Hemogenyx reports that on 12 November 2026, it treated the first patient in the second adult dose cohort of its HG-CT-1 Phase I CAR-T trial, using a dose twice that of the initial cohort. The company highlights that this escalation was recommended by the independent Data Safety Monitoring Board after the first cohort showed no dose-limiting toxicities. The announcement emphasizes that the administered product was the first HG-CT-1 manufactured by Made Scientific, following a manufacturing transfer in March 2026. Hemogenyx notes that five patients who had consented for the second cohort could not be treated due to rapid disease progression. The company underscores that all three first-cohort patients exhibited CAR-T expansion, persistence, and reductions in leukemic blast burden. The tone is factual and focused on operational milestones, with no forward-looking claims or promotional language. The narrative centers on clinical progress and manufacturing capability.

What the data suggests

The announcement confirms that the second adult dose cohort of the HG-CT-1 Phase I CAR-T trial is now underway, with the first patient treated at a dose double that of the initial cohort. The DSMB's recommendation to escalate dosing was based on the absence of dose-limiting toxicities in the three first-cohort patients, indicating an acceptable safety profile at the initial dose. All three first-cohort patients demonstrated both CAR-T expansion/persistence and reductions in leukemic blast burden, suggesting preliminary biological activity. The successful transfer of manufacturing to Made Scientific is evidenced by the use of their product in this cohort. Five consented patients were unable to receive treatment due to rapid disease progression, highlighting the challenges of treating this patient population. No financial, enrollment, or long-term efficacy data are disclosed. The update provides concrete operational progress but does not address broader clinical or commercial outcomes.

Analysis

The announcement is factual and proportionate, reporting realised milestones in Hemogenyx's Phase I CAR-T trial. All key claims are supported by specific operational data: the first patient in the second cohort has been treated, the dose escalation was DSMB-recommended, and all first-cohort patients showed CAR-T expansion, persistence, and reductions in leukemic blast burden. There are no forward-looking or aspirational claims; the language is focused on completed actions and observed outcomes. No exaggerated or promotional statements are present, and the tone matches the evidence provided. As this is a clinical-stage biotech update, the absence of financial data is normal and not a deficiency. The signal is weak_positive, reflecting genuine progress in a high-risk, early-stage context.

Risk flags

• ●Clinical risk remains high, as the trial is still in Phase I and only three patients have completed the first cohort, limiting the ability to draw robust safety or efficacy conclusions. Early positive signals do not guarantee later-stage success.
• ●Operational risk is evident from the fact that five consented patients in the second cohort could not be treated due to rapid disease progression, indicating potential challenges in patient recruitment and retention for this population.
• ●Manufacturing risk is partially mitigated by the successful transfer to Made Scientific, but this is the first use of their product in the trial, and ongoing consistency and scalability remain unproven at this stage.

Bottom line

Hemogenyx has advanced its HG-CT-1 Phase I CAR-T trial by treating the first patient in the second adult dose cohort at double the initial dose, following a DSMB recommendation based on a clean safety profile in the first three patients. All first-cohort patients showed CAR-T expansion and reductions in leukemic blast burden, providing early evidence of biological activity. The successful manufacturing transfer to Made Scientific has been operationalised, but this is the first clinical use of their product. The inability to treat five consented patients due to rapid disease progression underscores the fragility of this patient population and may impact future enrollment rates. No financial, regulatory, or long-term efficacy data are disclosed, so the announcement is strictly an operational update. Investors should interpret this as incremental but credible progress in a high-risk, early-stage clinical program, with the most important takeaway being the trial's continued advancement without observed safety issues at higher dosing.

Announcement summary

(LSE:HEMO) Hemogenyx Pharmaceuticals announced that on 12 November 2026, it treated the first patient in the second adult dose cohort of its HG-CT-1 Phase I CAR-T trial. The dose administered to this patient was equal to twice that given to the three patients in the first cohort. The escalation to this higher dose was recommended by the independent Data Safety Monitoring Board (DSMB) after the first cohort showed no dose-limiting toxicities. The product administered was the first HG-CT-1 manufactured by Made Scientific, following a manufacturing transfer announced in March 2026. Five patients who had consented for the second cohort could not be treated due to rapid disease progression. In the first cohort, all three patients demonstrated CAR-T expansion and persistence. Reductions in leukemic blast burden were observed in all three first-cohort patients. The company highlighted the successful manufacturing transfer to Made Scientific. The DSMB's recommendation to escalate the dose was based on safety data from the first cohort. The trial is identified as HG-CT-1 Phase I CAR-T. The announcement confirms that the second cohort is now underway. The company provided an update on both manufacturing and clinical progress. The escalation to a higher dose marks a key milestone in the trial. The company continues to monitor patient outcomes and safety. The announcement provides details on patient enrollment and treatment status. The company is advancing its CAR-T program as planned.

Disagree with this article?